Novartis Earnings Reports

Novartis delivered strong Q3 2025 results, driven by key brands like Kisqali and Kesimpta, along with continued innovation success including the FDA approval of Rhapsido.

Novartis delivered a robust Q2 2025 with $14.05 billion in revenue, driven by strong sales from Kisqali, Pluvicto, and Scemblix. Net income rose to $4.02 billion, and free cash flow increased significantly. The company raised its FY25 core operating income guidance.